Trump Action Archive

A searchable record of documented actions, compiled weekly from public sources.

1 event matching

Export CSVResearcher JSONAnalyst Newest first · Oldest first
Filtering Week: Week 90 × Attack target: Women × Clear all ☆ Save this search
Lower-confidence events are a Researcher feature. See plans →
Tier 1 carried by a primary record Corroborated 2+ independent news desks Every result is verified and democracy-related.

Open an event to see its evidence. Attack and trait tags link to their definitions

Oct 8, 2026 FDA extended its safety review of mifepristone into 2027 following pressure from anti-abortion groups Corroborated Economic Structure

A politically pressured, prolonged regulatory review of an approved medication risks weaponizing the FDA process to restrict reproductive-health access.

Independently corroborated by3 independent news desks
Supporting reportingSurfacings — do not carry alone

Supporting reports

  • FDA extended safety review of mifepristone into 2027 — The FDA announced that its ongoing safety review of mifepristone, the nation's primary abortion pill, will continue into 2027. The agency stated a report on findings is expected no later than March 2027, after which it will decide whether to impose new restrictions on the drug. The review was ordered by RFK Jr. following pressure from anti-abortion groups and their congressional allies seeking to restrict the pill's use.
Verified: Corroborated — 2+ independent news desks Week 90 – 2026-10-03–2026-10-09 wk90_ES_017